Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic LeukemiaJohn C. Byrd, Susan O’Brien, Richard R. Furman et al.|New England Journal of Medicine|2013Cited by 2.2k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic LeukemiaRichard R. Furman, Susan O’Brien, Jeff P. Sharman et al.|New England Journal of Medicine|2014Cited by 1.7k
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemiaEytan M. Stein, Martin S. Tallman, Courtney D. DiNardo et al.|Blood|2017Cited by 1.5k
Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international studyMichael J. Keating, Ian W. Flinn, Vinay Jain et al.|Blood|2002Cited by 946
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 studyAnthony R. Mato, Michael Wang, Nirav N. Shah et al.|The Lancet|2021Cited by 456